TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02959307

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Light Therapy
Description: Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Light Therapy
Description: Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions.
Study: NCT04167514

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Albumin solution administered intravenously
Study: NCT02959307

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Light Therapy
Description: The same device used for the actual transcranial light therapy is used as the sham device; The device, when set to sham, will mimic the actual transcranial light therapy; however, when set to sham the device does not emit skin and cranium penetrating light emitting diode light energy.
Study: NCT04674410

Intervention type: DRUG
Intervention: Antibiotic
Description: Empiric antibiotic therapy, subdivided according to Community Acquired Pneumonia coverage vs Hospital Acquired Pneumonia coverage
Study: NCT00330746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: 400 mg/m2 first dose then weekly at 250 mg/m2 until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1200 mg/m2 days 1 and 8 every 3 weeks for a maximum of 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1200 mg/m2 IV days 1 and 8 every 3 weeks for a maximum of 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: 400 mg/m2 first dose followed by 250 mg/m2 weekly
Study: NCT01755936

Intervention type: OTHER
Intervention: 72 hour Holter Monitor
Description: This will enable us to detect abnormal heart rhythms which may be associated with myocardial fibrosis

Intervention type: OTHER
Intervention: 72 hour Holter Monitor
Description: This will enable us to detect abnormal heart rhythms which may be associated with myocardial fibrosis
Study: NCT03825172

Intervention type: DIAGNOSTIC_TEST
Intervention: Caudal Epidural Ultrasonography
Description: Ultrasonographic Measurement

Intervention type: DIAGNOSTIC_TEST
Intervention: Caudal Epidural Ultrasonography
Description: Ultrasonographic Measurement
Study: NCT02025257

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Individually prescribed hospital based exercise in group two times a week, home-based exercise once a week. The exercise intervention consists of interval based aerobic exercise on a bicycle ergometer 30 minutes with intensity level at 13-17 at Borg scale, resistance exercises and balance exercises
Study: NCT01323166

Intervention type: PROCEDURE
Intervention: Excision of the levator muscle
Description: Cylindrical perineal excision including the levator muscle

Intervention type: PROCEDURE
Intervention: Excision of the levator muscle
Description: Cylindrical perineal excision including the levator muscle
Study: NCT00786734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Description: 4mg daily for 5-7 days before Percutaneous Coronary Intervention(PCI) and 4mg daily for 28 days after PCI

Intervention type: DRUG
Group type: OTHER
Intervention: Pitavastatin
Description: 4mg daily for 28 days after PCI
Study: NCT03033004

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Cryolipolysis
Description: Treatment will be a cold exposure of the subcutaneous fat for 60 minutes using the Polarys device. Polarys is a commercially available cryolipolitic device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contrast Cryolipolysis
Description: Treatment will consist of a heat exposure of the subcutaneous fat for 10 minutes followed by 60 minutes of cold exposure and 10 minutes of heat exposure again. Cold and heat will be provided by the Polarys device. Polarys is a commercially available cryolipolitic device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reperfusion Cryolipolysis
Description: Treatment will be a cold exposure of the subcutaneous fat for 60 minutes followed by 10 minutes of heat exposure using the Polarys device. Polarys is a commercially available cryolipolitic device.
Study: NCT04532944

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: imaging of energy dysfunction
Description: 7T sodium imaging, phosphorus spectroscopy and 3T diffusion-weighted spectroscopy

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: imaging of energy dysfunction
Description: 7T sodium imaging, phosphorus spectroscopy and 3T diffusion-weighted spectroscopy
Study: NCT02671227

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal bupivacaine 15 mg.
Description: intrathecal bupivacaine 15 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal bupivacaine 15 mg.
Description: intrathecal bupivacaine 15 mg.
Study: NCT02805101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biodentine
Description: Biodentine is going to be used as the sealing agent for the perforation.
Study: NCT04029441

Intervention type: OTHER
Intervention: the eradication Hp
Description: the eradication of Hp based on antimicrobial susceptibility test
Study: NCT01414595

Intervention type: GENETIC
Intervention: DNA analysis
Study: NCT02805101

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTA
Description: MTA is going to be used as the sealing agent for the perforation.
Study: NCT00556803

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency ablation
Description: radiofrequency ablation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE after RFA
Description: TACE after RFA within one month
Study: NCT01509846

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine: 2.6±0.8 x 10^8 vp/mL, 1 dose
Description: Shigella flexneri 2a whole cell killed vaccine (Sf2aWC): 2.6±0.8 x 10\^8 vp/mL administered on Day 0
Study: NCT00939510

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: All patients will receive GM-CSF at a dose of 250 mcg subcutaneously on Mondays, Wednesdays and Fridays every week. No dose escalation or de-escalations will be made to GM-CSF.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Lenalidomide will be administered at 25 mg/day orally on days 1-21 of a 28-day cycle. Initially 6 patients will be entered at the 25 mg/day level. If 0 or 1 patients have a dose limiting toxicity, then the 25 mg lenalidomide + GM-CSF 250 mcg subcutaneously on Mondays, Wednesdays and Fridays every week will be accepted as the phase II dose.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Prior to the initiation of each cycle of therapy for the first 3 cycles, and at discontinuation from study blood will be collected for assessments of a prostate cancer specific immune response.
Study: NCT04133337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib Mesylate Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: Camrelizumab for Injection
Study: NCT01509846

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine: 2.6±0.8 x 10^9 vp/mL, 3 doses
Description: Shigella flexneri 2a whole cell killed vaccine (Sf2aWC): 2.6±0.8 x 10\^9 vp/mL administered on Days 0, 28, and 56
Study: NCT01414595

Intervention type: GENETIC
Intervention: DNA methylation analysis

Intervention type: GENETIC
Intervention: RNA analysis

Intervention type: GENETIC
Intervention: gene expression analysis

Intervention type: GENETIC
Intervention: polymorphism analysis

Intervention type: OTHER
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Intervention: medical chart review
Study: NCT05980741

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high-quality nursing
Description: High-quality nursing

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical Care Pathway
Description: Clinical Care Pathway

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roy Adaptation Model
Description: Roy Adaptation Model
Study: NCT04067336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziftomenib
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziftomenib
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziftomenib
Description: Oral administration
Study: NCT01423136

Intervention type: DEVICE
Intervention: Remote ECG monitoring Spacelab SL 1050
Description: If ischemia noted, Sx will be notified and currently accepted treatments of myocardial ischemia will be recommended.
Study: NCT02415569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Bowel Prep (2L PEG-ELP)
Description: Subjects whose bristol stool forms are type 1 or 2, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure.
Study: NCT05619952

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mushroom Powder
Description: Ground shiitake mushrooms or ground white button mushrooms

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mushroom Powder
Description: Ground shiitake mushrooms or ground white button mushrooms
Study: NCT03487172

Intervention type: DEVICE
Group type: OTHER
Intervention: poly-L-lactic acid to right knee
Description: Subjects will receive PLLA injections to the right knee and bacteriostatic water to the left.

Intervention type: DEVICE
Group type: OTHER
Intervention: poly-L-lactic acid to left knee
Description: Subjects will receive PLLA injections to the left knee and bacteriostatic water to the right.
Study: NCT02415569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2L PEG-ELP and 10mg bisacodyl
Description: Subjects whose bristol stool forms are type 1 or 2, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure and 10mg bisacodyl the day before procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Bowel Prep (2L PEG-ELP)
Description: Subjects whose bristol stool forms are type 3 to 7, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure.
Study: NCT02709252

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PVI and deltaPP after trendelenburg position change
Description: Comparison of hemodynamic parameters during surgery after position change
Study: NCT02681744

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: 24-weeks of progressive strength training
Study: NCT00468650

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil citrate
Description: Tablets, 50mg and 100mg , Medication will be taken orally with a glass of water approximately one hour (30 min to 4 hours) before sexual activity. Subjects are to take one dose in any calendar day.Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil 100 mg PRN for the following four weeks.
Study: NCT02468063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose terlipressin
Description: Terlipressin-2mg (low dose )
Study: NCT01509846

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine: 2.6±0.8 x 10^10 vp/mL, 3 doses
Description: Shigella flexneri 2a whole cell killed vaccine (Sf2aWC): 2.6±0.8 x 10\^10 vp/mL administered on Days 0, 28, and 56

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine: 2.6±0.8 x 10^11 vp/mL, 3 doses
Description: Shigella flexneri 2a whole cell killed vaccine (Sf2aWC): 2.6±0.8 x 10\^11 vp/mL administered on Days 0, 28, and 56
Study: NCT02468063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Noradrenaline
Description: Noradrenaline at 7.5 mcg/min, maximum of 60mcg/min. stepped up every 15 min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Noradrenaline
Description: Noradrenaline- 3.75 mcg/min to 30 mcg/min. stepped up every 15 min
Study: NCT03201250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib:~Phase I: Level -1 = 20 mg or Level 0 = 40 mg or Level +1 = 60 mg, PO daily on days 1-28 Phase II: One of phase I dosing levels identified as MTD, PO daily on days 1-28~Carfilzomib: 27 mg/m2 IV over 10 min on days 1, 2, 8, 9, 15, 16~Dexamethasone: 40 mg PO/IV on days 1, 8,15 and 22 (for patient age ≥ 75, acceptable to be given as 20 mg PO/IV on days 1, 2, 8, 9, 15, 16, 22, 23)
Study: NCT02351583

Intervention type: DEVICE
Intervention: CytoCam
Description: The side-stream darkfield camera ( CytoCam) will be put under the subjects tongue for 5-10 minutes. Multiple pictures of the small blood vessels will be taken.

Intervention type: DEVICE
Intervention: CytoCam
Description: The side-stream darkfield camera ( CytoCam) will be put under the subjects tongue for 5-10 minutes. Multiple pictures of the small blood vessels will be taken.

Intervention type: DEVICE
Intervention: NIRS Artinis PortaLite with OxySoft softwear
Description: . The NIRS probe will be applied to one of the patient's thenar muscle and over the patient forehead and tissue oxygenation (TOI) will be recorded for 5 minutes.

Intervention type: DEVICE
Intervention: NIRS Artinis PortaLite with OxySoft softwear
Description: . The NIRS probe will be applied to one of the patient's thenar muscle and over the patient forehead and tissue oxygenation (TOI) will be recorded for 5 minutes.
Study: NCT03365167

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: LANAP (Laser Assisted New Attachment Procedure)
Description: radiation of Nd:YAG laser in periodontal pocket

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: LANAP off
Description: radiation of Nd:YAG laser in off mode in periodontal pocket
Study: NCT01509846

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: 1-3 doses
Description: Placebo administered on Day 0 (if 1 dose) or Day 0, 28, and 56 (3 doses)
Study: NCT05508178

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus GI.4 / GII.4 Bivalent VLP Vaccine (100 µg)
Description: Norovirus: 50 µg GI.4 VLP + 50 µg GII.4 VLP without adjuvant
Study: NCT01400919

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Protégé® EverFlex™ Self-Expanding Stent System, and Protégé® GPS™ Self-Expanding Stent System.
Description: Implantation of one or more study devices in the common and/or external iliac artery.
Study: NCT01216696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: Eligible patients will receive 10 mg/kg ipilimumab every 3 weeks during a 10-week induction period, followed by a radiological assessment in week 12. Patients with clinical benefit will continue with an ipilimumab administration every 3 months starting at week 24 up to week 48 until the end of the study or until disease progression, toxicities requiring discontinuation , withdrawal of consent,pregnancy, death or lost to follow up whichever occurs first.
Study: NCT01889212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 11C-erlotinib PET/CT
Study: NCT01832935

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: The starting dose of insulin Glargine was 24 units per day (0.2-0.6 unit/kg) in 2 divided doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin NPH
Description: The starting dose of insulin NPH was 24 units per day (0.2-0.6 unit/kg) in 2 divided doses
Study: NCT04293094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 650
Description: AMG 650 administered orally as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 650
Description: AMG 650 administered orally as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 650
Description: AMG 650 administered orally as a tablet.
Study: NCT01877226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol
Description: Tapentadol tamper resistant prolonged-release formulation (TRF) will be administered as 250 milligram oral tablet once (in the morning, 30 minutes after breakfast) on Day 1 and 6, and twice daily (in the morning, 30 minutes after breakfast and in the evening) on Day 4 and 5.
Study: NCT05508178

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus GI.4 / GII.4 Bivalent VLP Vaccine (300 µg)
Description: Norovirus: 150 µg GI.4 VLP + 150 µg GII.4 VLP without adjuvant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Norovirus vaccine (rNV-2v) vehicle without antigen
Study: NCT02522169

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: This is a randomized, prospective, parallel -controlled study, simple blinded and multicenter designed. Study centers are the Department of Child and Adolescent Medicine of the Ernst von Bergmann Hospital, Potsdam, and the Department of Child and Adolescent Medicine of Charité, Berlin.~We estimate a sample size of 50 patients per center. Study inclusion begins with given consent of the patient and the legal guardian. Patients will be randomized in control- and intervention group separately for Cohn's disease. An equal age and gender distribution is targeted for both control and intervention group. Sub groups will be formed depending on the time span from completed Infliximab induction to study enrollment (group A\< 6month, group B \< 6 month). Observation period is one year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: This is a randomized, prospective, parallel -controlled study, simple blinded and multicenter designed. Study centers are the Department of Child and Adolescent Medicine of the Ernst von Bergmann Hospital, Potsdam, and the Department of Child and Adolescent Medicine of Charité, Berlin.~We estimate a sample size of 50 patients per center. Study inclusion begins with given consent of the patient and the legal guardian. Patients will be randomized in control- and intervention group separately for Cohn's disease. An equal age and gender distribution is targeted for both control and intervention group. Sub groups will be formed depending on the time span from completed Infliximab induction to study enrollment (group A\< 6month, group B \< 6 month). Observation period is one year.
Study: NCT02544750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P
Description: Yellow oily solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
Study: NCT03686878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lifitegrast
Description: Lifitegrast used twice a day
Study: NCT03400410

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education Arm
Description: The educational video will be an overview with brief pros and cons of all types of available hormonal contraception. There will be emphasis on the importance of condom use as part of dual method protection.
Study: NCT03301337

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meat protein absorption
Description: Meat protein absorption when digested together with a full meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meat protein absorption
Description: Meat protein absorption when digested together with a full meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meat protein absorption
Description: Meat protein absorption when digested together with a full meal.
Study: NCT04155528

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: The intervention is listening to selected prerecorded music, specific Raga, on the individual CD player.
Study: NCT03483792

Intervention type: BIOLOGICAL
Intervention: Plasma dosage
Description: 4 x 7 ml of blood punction at each control visit of the three trimesters of pregnancy

Intervention type: BIOLOGICAL
Intervention: Plasma dosage
Description: 4 x 7 ml of blood punction at each control visit of the three trimesters of pregnancy

Intervention type: GENETIC
Intervention: placental biopsy
Description: Immediately following delivery (\<12h postpartum), placental biopsies (Collection of 4 placental fragments)

Intervention type: GENETIC
Intervention: placental biopsy
Description: Immediately following delivery (\<12h postpartum), placental biopsies (Collection of 4 placental fragments)
Study: NCT04677543

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALIS
Description: Inhalation via nebulization over approximately 6 to 15 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azithromycin
Description: Oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethambutol
Description: Oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ethambutol
Description: Oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ELC
Description: Inhalation via nebulization over approximately 6 to 15 minutes.
Study: NCT04192266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: 2.0 mg of estradiol will be taken by mouth by the study participant 5-6 hours before each of 5 PE treatment sessions (Session 2- 6)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: 2.0 mg placebo pills will be taken by mouth by the study participant 5-6 hours before each of 5 PE treatment sessions ( Sessions 2-6)
Study: NCT03825172

Intervention type: DIAGNOSTIC_TEST
Intervention: Caudal Epidural Ultrasonography
Description: Ultrasonographic Measurement
Study: NCT02273037

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fetal heart rate Doppler
Description: A wind-up, handheld fetal heart rate monitor Doppler developed by Power-free Education Technology Doppler (www.pet.org.za)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partograph
Description: Graphical documentation of labour progress, and maternal and fetal well-being.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Partograph
Description: Graphical documentation of labour progress, and maternal and fetal well-being.
Study: NCT02030470

Intervention type: OTHER
Group type: OTHER
Intervention: Fotosan®630. LED lamp. Toluidinblue. Photoactivated disinfection